Figure 3. Rationale for combining RTK-targeted and mTOR-targeted therapies.
Arrow thickness is proportional to signal strength. Font weight of ‘malignancy’ is proportional to malignant effects.
LIG: Ligand; PIP2: Phosphatidylinositol-3,4,-bisphosphate; PIP3: Phosphatidylinositol-3,4,5-triphosphate; RTK: Receptor tyrosine kinase.